115 related articles for article (PubMed ID: 1675969)
1. The effects of low-dose Bay-m-1099 (Miglitol) on serum lipids and liver enzyme activity of obese and obese-diabetic corpulent rats.
Tulp OL; Szepesi B; Michaelis OE; DeBouno JF
Comp Biochem Physiol C Comp Pharmacol Toxicol; 1991; 99(1-2):241-6. PubMed ID: 1675969
[TBL] [Abstract][Full Text] [Related]
2. The effects of the intestinal glucosidase inhibitory BAY M 1099 (miglitol) on glycemic status of obese-diabetic rats.
DeBouno JF; Michaelis OE; Tulp OL
Gen Pharmacol; 1993 Mar; 24(2):509-15. PubMed ID: 8482529
[TBL] [Abstract][Full Text] [Related]
3. Glucose tolerance and insulin resistance in the JCR:LA-corpulent rat: effect of miglitol (Bay m1099).
Russell JC; Graham SE; Dolphin PJ
Metabolism; 1999 Jun; 48(6):701-6. PubMed ID: 10381143
[TBL] [Abstract][Full Text] [Related]
4. Miglitol (BAY m 1099) treatment of diabetic hypothalamic-dietary obese rats improves islet response to glucose.
Axen KV; Li X; Sclafani A
Obes Res; 1999 Jan; 7(1):83-9. PubMed ID: 10023734
[TBL] [Abstract][Full Text] [Related]
5. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.
Johnston PS; Feig PU; Coniff RF; Krol A; Davidson JA; Haffner SM
Diabetes Care; 1998 Mar; 21(3):409-15. PubMed ID: 9540024
[TBL] [Abstract][Full Text] [Related]
6. Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes.
Heinz G; Komjati M; Korn A; Waldhäusl W
Eur J Clin Pharmacol; 1989; 37(1):33-6. PubMed ID: 2687007
[TBL] [Abstract][Full Text] [Related]
7. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients.
Johnston PS; Coniff RF; Hoogwerf BJ; Santiago JV; Pi-Sunyer FX; Krol A
Diabetes Care; 1994 Jan; 17(1):20-9. PubMed ID: 8112185
[TBL] [Abstract][Full Text] [Related]
8. Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.
Schnack C; Prager RJ; Winkler J; Klauser RM; Schneider BG; Schernthaner G
Diabetes Care; 1989 Sep; 12(8):537-43. PubMed ID: 2673693
[TBL] [Abstract][Full Text] [Related]
9. Miglitol, a new alpha-glucosidase inhibitor.
Sels JP; Huijberts MS; Wolffenbuttel BH
Expert Opin Pharmacother; 1999 Nov; 1(1):149-56. PubMed ID: 11249557
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of glycemic and hormonal responses after repetitive sucrose and starch loads by different doses of the alpha-glucosidase inhibitor miglitol (BAY m 1099) in man.
Lembcke B; Fölsch UR; Gatzemeier W; Ebert R; Siegel E; Creutzfeldt W
Pharmacology; 1991; 43(6):318-28. PubMed ID: 1784628
[TBL] [Abstract][Full Text] [Related]
11. Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
Johnson AB; Taylor R
Diabetes Care; 1996 Jun; 19(6):559-63. PubMed ID: 8725851
[TBL] [Abstract][Full Text] [Related]
12. Miglitol may have a blood glucose lowering effect unrelated to inhibition of alpha-glucosidase.
Joubert PH; Foukaridis GN; Bopape ML
Eur J Clin Pharmacol; 1987; 31(6):723-4. PubMed ID: 3549325
[TBL] [Abstract][Full Text] [Related]
13. Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers.
Sels JP; Nauta JJ; Menheere PP; Wolffenbuttel BH; Nieuwenhuijzen Kruseman AC
Br J Clin Pharmacol; 1996 Oct; 42(4):503-6. PubMed ID: 8904624
[TBL] [Abstract][Full Text] [Related]
14. Adaptation in enzyme (metabolic) pathways to obesity, carbohydrate diet and to the occurrence of NIDDM in male and female SHR/N-cp rats.
Yamini S; Carswell N; Michaelis OE; Szepesi B
Int J Obes Relat Metab Disord; 1992 Oct; 16(10):765-74. PubMed ID: 1330956
[TBL] [Abstract][Full Text] [Related]
15. In vitro study of the effect of miglitol on carbohydrate digestion and intestinal metabolism in normal and non-insulin-dependent diabetic rats.
Tormo MA; Ropero MF; Nieto M; Martinez IM; Campillo JE
Can J Physiol Pharmacol; 1996 Nov; 74(11):1196-203. PubMed ID: 9028577
[TBL] [Abstract][Full Text] [Related]
16. Effect of alpha-glucosidase inhibition on glucose profiles in insulin dependent diabetes.
Hillman RJ; Scott M; Gray RS
Diabetes Res; 1989 Feb; 10(2):81-4. PubMed ID: 2663321
[TBL] [Abstract][Full Text] [Related]
17. Effect of miglitol administration to non-insulin-dependent diabetic rats.
Tormo MA; Ropero MF; Nieto M; Martinez IM; Campillo JE
Gen Pharmacol; 1998 Jan; 30(1):125-9. PubMed ID: 9457493
[TBL] [Abstract][Full Text] [Related]
18. Effects of miglitol, an alpha-glucosidase inhibitor, on glycaemic status and histopathological changes in islets in non-obese, non-insulin-dependent diabetic Goto-Kakizaki rats.
Goda T; Suruga K; Komori A; Kuranuki S; Mochizuki K; Makita Y; Kumazawa T
Br J Nutr; 2007 Oct; 98(4):702-10. PubMed ID: 17537288
[TBL] [Abstract][Full Text] [Related]
19. The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism?
Joubert PH; Venter HL; Foukaridis GN
Br J Clin Pharmacol; 1990 Sep; 30(3):391-6. PubMed ID: 2223417
[TBL] [Abstract][Full Text] [Related]
20. Postprandial glycemic control, hormonal effects and carbohydrate malabsorption during long-term administration of the alpha-glucosidase inhibitor miglitol.
Lembcke B; Diederich M; Fölsch UR; Creutzfeldt W
Digestion; 1990; 47(1):47-55. PubMed ID: 2292349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
